Please login to the form below

Santen

This page shows the latest Santen news and features for those working in and with pharma, biotech and healthcare.

off competition from Novartis, Santen UK and Tillotts Pharma UK.

NICE no for new eye disease drug

NICE's preliminary recommendation has been to ask Santen Pharmaceutical for more information on Ikervis (ciclosporin) for treating severe keratitis in adults with dry eye disease which has not improved despite
Antibiotics among 7 new drugs backed by EMA

The final two drugs to feature in the list of positive opinions were Santen's Ikervis (ciclosporin) for the treatment of the eye condition severe keratitis and MDCO's Raplixa (human
Meeting with resistance

Low-grade B-cell lymphoma; mantle cell lymphoma. Japan. Diquafosol. Diquas Ophthalmic Solution 3% (Santen Pharmaceutical).
Inspire drops cystic fibrosis programme

net sales of Diquas (diquafosol) for dry eye, which is marketed in Japan by Santen but has not been approved in the US.
Thin on the ground

UK. Dorzolamide/timolol. Cosopt (Santen Pharmaceutical Co). Glaucoma and ocular hypertension. Japan.

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

The good, the bad and the ugly

Ophthalmology. Ophthalmology is dominated by a small number of the same therapies marketed by different companies in different regions; Regeneron, Bayer and Santen all market Eylea, whereas Novartis and Roche market
Deal Watch table for May 2014

653. Merck &Co / Santen. Asset / product acquisition. 2. Ophthalmology products in Japan, Europe and Asia Pacific with sales of $400m.
Pharma deals during May 2014

Not content with the Bayer deals, Merck &Co also divested its ophthalmic business (mainly Timolol) in Japan, Asia Pacific and Europe to its licensee Santen.
Deal Watch table for March 2014

22. Tracon Pharmaceuticals/ Santen Pharmaceutical Co. Licence. Tracon's anti‐endoglin antibodies, including TRC105 for wet AMD (p2).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Luis Iglesias heads Santen EMEA

His promotion sees him succeed Shigeo Taniuchi. Luis Iglesias has been promoted as Santen’s EMEA head, a move that sees him succeed Shigeo Taniuchi - who returns to Japan to become ... Iglesias initially joined Santen in 2017 as its senior vice
Paolo Casati named as general manager of Santen Italy

Has over 30 years of experience in the sector. Eye care specialist Santen Pharma has appointed Paolo Casati as general manager of its Italian subsidiary. ... I am very excited to join the team to establish Santen Italy as one of the major companies of